AASLD 2020: Resolution and Fibrosis Regression With Lanifibranor Are Similar in Patients With and Without Type 2 Diabetes
The investigation drug is a pan-PPAR agonist.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.